Search results for "Substantia nigra"

showing 10 items of 90 documents

Medicinal Plants and Natural Products as Potential Sources for Antiparkinson Drugs

2016

Parkinsonʼs disease is a progressive neurodegenerative dysfunction characterized by the loss of pigmented dopaminergic neurons of the nigrostriatal system with a consequent dopamine decrease. The reduction of dopamine levels produces neuronal damage, depigmentation of the substantia nigra, and the presence of intracellular inclusions in dopaminergic neurons. Treatments for Parkinsonʼs disease aim for improving these motor symptoms by increasing the dopaminergic signal in the striatum with levodopa in combination with enzyme inhibitors or anticholinergic drugs. Nevertheless, natural products can act as neuroprotective agents by reducing the progression of the disease and the inflammatory pro…

0301 basic medicineLevodopaPharmaceutical ScienceSubstantia nigraPharmacologyBiologyNeuroprotectionAnalytical ChemistryAntiparkinson Agents03 medical and health sciences0302 clinical medicineDopamineDrug DiscoverymedicineAnimalsHumansPharmacologyBiological ProductsPlants MedicinalPlant ExtractsOrganic ChemistryDopaminergicAntiparkinsonian AgentAntiparkinson drug030104 developmental biologynervous systemComplementary and alternative medicineAntiparkinson AgentsMolecular Medicine030217 neurology & neurosurgeryPhytotherapymedicine.drugPlanta Medica
researchProduct

Intranasal Administration of Extracellular Vesicles Derived from Human Teeth Stem Cells Improves Motor Symptoms and Normalizes Tyrosine Hydroxylase E…

2018

Abstract Parkinson's disease (PD) is the second most common neurodegenerative disorder affecting millions of people worldwide. At present, there is no effective cure for PD; treatments are symptomatic and do not halt progression of neurodegeneration. Extracellular vesicles (EVs) can cross the blood–brain barrier and represent promising alternative to the classical treatment strategies. In the present study, we examined therapeutic effects of intranasal administration of EVs derived from human exfoliated deciduous teeth stem cells (SHEDs) on unilateral 6-hydroxydopamine (6-OHDA) medial forebrain bundle (MFB) rat model of PD. CatWalk gait tests revealed that EVs effectively suppressed 6-OHDA-…

0301 basic medicineMaleCell signalingParkinson's diseaseParkinson's diseaseStriatumPharmacology0302 clinical medicineMedicineMedial forebrain bundleAdult stem cellsStem CellsNeurodegenerationParkinson DiseaseGeneral MedicineAnimal modelsSubstantia NigraDifferentiationmedicine.symptom:MEDICINE::Physiology and pharmacology::Pharmacological research [Research Subject Categories]Tyrosine 3-MonooxygenaseCellular therapySubstantia nigraLesion03 medical and health sciencesExtracellular VesiclesMicroscopy Electron TransmissionTissue Engineering and Regenerative MedicineAnimalsHumansRats WistarOxidopamineAdministration IntranasalAgedHydroxydopamineTyrosine hydroxylasebusiness.industryCell Biologymedicine.diseaseCorpus StriatumRatsDisease Models Animal030104 developmental biologynervous systemMesenchymal stem cellsbusinessTooth030217 neurology & neurosurgeryDevelopmental BiologyStem cells translational medicine
researchProduct

Dopamine, Noradrenaline and Serotonin Receptor Densities in the Striatum of Hemiparkinsonian Rats following Botulinum Neurotoxin-A Injection.

2017

Abstract Parkinson’s disease (PD) is characterized by a degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) that causes a dopamine (DA) deficit in the caudate-putamen (CPu) accompanied by compensatory changes in other neurotransmitter systems. These changes result in severe motor and non-motor symptoms. To disclose the role of various receptor binding sites for DA, noradrenaline, and serotonin in the hemiparkinsonian (hemi-PD) rat model induced by unilateral 6-hydroxydopamine (6-OHDA) injection, the densities of D1, D2/D3, α1, α2, and 5HT2A receptors were longitudinally visualized and measured in the CPu of hemi-PD rats by quantitative in vitro receptor autorad…

0301 basic medicineMalemedicine.medical_specialtyApomorphine5-HT2A receptorNeurotoxinsSubstantia nigraMotor ActivityFunctional LateralityAntiparkinson Agents03 medical and health sciences0302 clinical medicineDopamine receptor D1Parkinsonian DisordersDopamine receptor D3DopamineInternal medicinemedicineAnimalsddc:610Longitudinal StudiesBotulinum Toxins Type ARats WistarReceptorOxidopamine5-HT receptorChemistryGeneral NeuroscienceDopaminergicCorpus StriatumReceptors Neurotransmitter030104 developmental biologyEndocrinologyDopamine Agonists030217 neurology & neurosurgerymedicine.drugNeuroscience
researchProduct

The predictive power of transcranial sonography in movement disorders: a longitudinal cohort study.

2018

Transcranial sonography (TCS) is a noninvasive, easily performed, and commonly available neuroimaging technique useful for the study of brain parenchyma in movement disorders. This tool has been increasingly used in the diagnosis of Parkinson’s disease and atypical parkinsonism. The aim of the study was to evaluate the applicability of this technique as supportive tool in the early diagnosis of movement disorders. We performed TCS on 315 individuals which were diagnosed as healthy controls or affected by idiopathic Parkinson’s disease, monogenetic subtypes of Parkinson’s disease, atypical parkinsonism, and Dementia with Lewy bodies. Five TCS diagnostic patterns were defined on the basis of …

0301 basic medicineMalemedicine.medical_specialtyMovement disordersNeurologyUltrasonography Doppler TranscranialConcordanceDementia with Lewy bodiesDermatologyDiseaseCohort Studies03 medical and health sciences0302 clinical medicineNeuroimagingPredictive Value of TestsInternal medicineSubstantia nigramedicineLenticular nucleiHumansNeuroradiologyAgedMovement DisordersDementia with Lewy bodiesbusiness.industryfungiGeneral MedicineMiddle Agedmedicine.diseasePsychiatry and Mental health030104 developmental biologyAtypical parkinsonismIdiopathic Parkinson’s diseaseTranscranial sonographySettore MED/26 - NeurologiaFemaleNeurology (clinical)Neurosurgerymedicine.symptombusiness030217 neurology & neurosurgeryNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
researchProduct

Genetic and constitutional factors are major contributors to substantia nigra hyperechogenicity

2017

9 páginas, 2 figuras, 4 tablas

0301 basic medicineMalemedicine.medical_specialtyMovement disordersScienceSubstantia nigraDiseaseComorbidityArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansGenetic Predisposition to DiseaseFamily historyAmyotrophic lateral sclerosisPsychiatryGenetic Association StudiesGenetic testingAgedUltrasonographyMultidisciplinarymedicine.diagnostic_testbusiness.industryQCase-control studyRNeurodegenerative DiseasesMiddle Agedmedicine.diseaseComorbiditySubstantia Nigra030104 developmental biologyCase-Control StudiesMutationMedicineFemalemedicine.symptombusiness030217 neurology & neurosurgeryBiomarkers
researchProduct

Lorcaserin bidirectionally regulates dopaminergic function site-dependently and disrupts dopamine brain area correlations in rats

2020

Abstract Lorcaserin, which is a selective agonist of serotonin2C receptors (5-HT2CRs), is a new FDA-approved anti-obesity drug that has also shown therapeutic promise in other brain disorders, such as addiction and epilepsy. The modulation of dopaminergic function might be critical in the therapeutic effect of lorcaserin, but its exact effect is unknown. Here, we studied the effect of the peripheral administration of lorcaserin on the ventral tegmental area (VTA), the substantia nigra pars compacta (SNc) dopaminergic neural activity, dopamine (DA) dialysis levels in the nucleus accumbens and striatum and on DA tissue levels in 29 different rat brain regions. Lorcaserin (5–640 μg/kg, i.v.) m…

0301 basic medicineMalemedicine.medical_specialtySerotoninDopamineSubstantia nigraStriatumNucleus accumbensSettore BIO/09 - FisiologiaLorcaserinIntracerebral microdialysisRats Sprague-DawleyDose-Response Relationship03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineSingle cell extracellular recordingsRewardDopamineInternal medicineReceptor Serotonin 5-HT2CmedicineAnimals5-HT2CObesityPharmacologyDose-Response Relationship DrugPars compactaChemistryDopaminergic NeuronsDopaminergicBrainNeurochemistryBenzazepinesSerotonin2C receptorRatsVentral tegmental area030104 developmental biologyEndocrinologymedicine.anatomical_structurenervous systemSprague-DawleyDrugIntracerebral microdialysis; Neurochemistry; Obesity; Reward; Serotonin2C receptor; Single cell extracellular recordings; Animals; Benzazepines; Brain; Dopamine; Dopaminergic Neurons; Dose-Response Relationship Drug; Male; Rats; Rats Sprague-Dawley; Receptor Serotonin 5-HT2C; Serotonin 5-HT2 Receptor AgonistsIntracerebral microdialysi030217 neurology & neurosurgerySerotonin 5-HT2 Receptor Agonistsmedicine.drugReceptor
researchProduct

Acute and chronic nicotine exposures differentially affect central serotonin 2A receptor function : focus on the lateral habenula

2020

Nicotine addiction is a serious public health problem causing millions of deaths worldwide. Serotonin (5-hydroxytryptamine

0301 basic medicineMalenucleus accumbensdorsal raphe nucleusmedicine.medical_treatmentstriatumPharmacologySmoking cessationSettore BIO/09 - FisiologiaSerotonin -- Receptorslcsh:ChemistryNicotineRats Sprague-DawleyNicotine addiction -- Treatment0302 clinical medicine5-HT2Asubstantia nigra pars compactaReceptor Serotonin 5-HT2Adentate gyruslcsh:QH301-705.5Spectroscopymedia_commonNeuronsGeneral MedicineDorsal raphe nucleu5-HT<sub>2C</sub>RComputer Science ApplicationsVentral tegmental areamedicine.anatomical_structuredepressionaddiction5-HT2CR; Addiction; Dentate gyrus; Depression; Dorsal raphe nucleus; Medial prefrontal cortex; Nucleus accumbens; Striatum; Substantia nigra pars compacta; Ventral tegmental area; Animals; Habenula; Male; Neurons; Nicotine; Rats; Rats Sprague-Dawley; Receptor Serotonin 5-HT2A; SerotoninReceptormedicine.drugAgonistNicotineSerotoninmedicine.drug_classmedia_common.quotation_subjectCentral nervous systemventral tegmental area substantia nigra pars compactaventral tegmental areaNucleus accumbensDentate gyruCatalysisArticleInorganic Chemistry03 medical and health sciencesmental disordersmedicineAnimalsNucleus accumbenPhysical and Theoretical ChemistryMolecular BiologyHabenulabusiness.industryAddictionOrganic ChemistryRats5-HT2CR030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Smoking cessationSprague-DawleySerotoninbusinessReceptors Serotonin 5-HT2030217 neurology & neurosurgerymedial prefrontal cortex
researchProduct

Enhanced activity of glycolytic enzymes in Drosophila and human cell models of Parkinson's disease based on DJ-1 deficiency

2020

ABSTRACTParkinson’s disease (PD) is a neurodenerative debilitating disorder characterized by progressive disturbances in motor, autonomic and psychiatric functions. The pathological hallmark of PD is the loss of dopaminergic neurons in the substantia nigra pars compacta, which causes striatal dopamine deficiency. Although most PD cases are sporadic (iPD), approximately 5-10% of all patients suffer from monogenic PD forms caused by highly penetrant rare mutations segregating with the disease in families (fPD). One of the genes linked to monogenic PD is DJ-1. Mutations in DJ-1 cause autosomal recessive early-onset forms of fPD; however, it has been shown that an over-oxidized and inactive for…

0301 basic medicineParkinson's diseaseProtein CarbonylationProtein Deglycase DJ-1MutantNerve Tissue ProteinsSubstantia nigraBiologymedicine.disease_causeBiochemistryNeuroprotection03 medical and health sciences0302 clinical medicinePhysiology (medical)medicineAnimalsDrosophila ProteinsHumansGlycolysisGeneLoss functionPars compactaChemistryDopaminergicParkinson Diseasemedicine.diseasePhenotypeCell biologyOxidative Stress030104 developmental biologyDrosophilaGlycolysis030217 neurology & neurosurgeryOxidative stressFree Radical Biology and Medicine
researchProduct

Identification of potential therapeutic compounds for Parkinson's disease using Drosophila and human cell models.

2017

Abstract Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. It is caused by a loss of dopaminergic neurons in the substantia nigra pars compacta, leading to a decrease in dopamine levels in the striatum and thus producing movement impairment. Major physiological causes of neurodegeneration in PD are oxidative stress (OS) and mitochondrial dysfunction; these pathophysiological changes can be caused by both genetic and environmental factors. Although most PD cases are sporadic, it has been shown that 5–10% of them are familial forms caused by mutations in certain genes. One of these genes is the DJ-1 oncogene, which is involved in an early…

0301 basic medicineParkinson's diseaseProtein Deglycase DJ-1Drug Evaluation PreclinicalSubstantia nigraNerve Tissue ProteinsBiologymedicine.disease_causeBiochemistryAnimals Genetically Modified03 medical and health sciences0302 clinical medicineDopaminePhysiology (medical)Cell Line TumorDrug DiscoverymedicineAnimalsDrosophila ProteinsHumansGeneticsMutationPars compactaNeurodegenerationDopaminergicParkinson Diseasemedicine.diseaseDisease Models AnimalOxidative Stress030104 developmental biologyGene Knockdown TechniquesMutationCancer researchDrosophila030217 neurology & neurosurgeryOxidative stressLocomotionmedicine.drugFree radical biologymedicine
researchProduct

Contribution of cholesterol and oxysterols to the pathophysiology of Parkinson's disease

2016

International audience; Neurodegenerative diseases are a major public health issue worldwide. Some countries, including France, have engaged in research into the causes of Parkinson's disease, Alzheimer's disease, and multiple sclerosis and the management of these patients. It should lead to a better understanding of the mechanisms leading to these diseases including the possible involvement of lipids in their pathogenesis. Parkinson's disease is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra and the accumulation of α-synuclein (Lewy bodies). Several in vivo studies have shown a relationship between the lipid profile [chole…

0301 basic medicinePathologymedicine.medical_specialtyParkinson's diseaseOxysterolParkinson's diseasePresynaptic TerminalsSubstantia nigraDiseaseBiologyBioinformaticsBiochemistryPathogenesisProtein Aggregates03 medical and health scienceschemistry.chemical_compoundOxysterol0302 clinical medicinePhysiology (medical)medicineHumans[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyAlpha-synucleinCell Deathmedicine.diagnostic_testDopaminergic NeuronsMultiple sclerosisParkinson DiseaseOxysterols[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismmedicine.diseaseSubstantia NigraCholesterol030104 developmental biologychemistryalpha-Synucleinlipids (amino acids peptides and proteins)Lipid profileOxidation-Reduction030217 neurology & neurosurgeryFree Radical Biology and Medicine
researchProduct